Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants

Efficacy and Safety of Nivolumab in Metastatic Renal Cell Cancer Patients - Japanese Real-World Data Through Clinical Chart Review

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03568435

Enrollment

212

Registered

2018-06-26

Start date

2018-02-14

Completion date

2020-12-21

Last updated

2022-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Cancer, Renal Cancer

Brief summary

A non-interventional, medical record review of clinical data collected from Japanese participants with recurring kidney cancer

Interventions

OTHERNon-Interventional

Non-Interventional

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* A patient with RCC with distant metastasis treated for the first time with nivolumab

Exclusion criteria

* Patients who have participated in some trials with immuno-checkpoint blockade before or after treatment with nivolumab after diagnosis with RCC Other protocol defined inclusion/

Design outcomes

Primary

Measure	Time frame
Incidence of serious adverse events	36 months
Duration of response	6 months
Incidence of adverse events	36 months
Overall survival status	6 months
Best overall response	6 months
Progression free survival rate	6 months
Disease free survival	6 months
Objective response rate	6 months

Secondary

Measure	Time frame
Distribution of socio-demographic characteristics	36 months
Distribution of clinical characteristics	36 months

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026